Is there a rationale for the use of botulinum toxin in the treatment of Androgenetic Alopecia

Androgenetic alopecia (AGA) is the most common form of alopecia in men and women. It is a chronic and progressive condition, characterized by a decline in the metabolic activities, with progressive miniaturization of the hair follicle. It may compromise self-esteem and quality of life in several affected individuals.1 Currently, the FDA approved drugs for the treatment of AGA are only topical minoxidil in women and topical minoxidil and oral finasteride in men.1 Recently, studies have pointed out injectable Botulinum toxin (BT) as an emergent possible adjuvant treatment for AGA.